C(OC([N:8]1[CH2:14][CH2:13][CH2:12][N:11]([C:15]2[N:23]([C:24]3[CH:29]=[CH:28][CH:27]=[CH:26][CH:25]=3)[C:18]3=[N:19][CH:20]=[CH:21][CH:22]=[C:17]3[C:16]=2[CH:30]=[O:31])[CH2:10][CH2:9]1)=O)(C)(C)C.FC(F)(F)C(O)=O.C(#N)C.CCOCC>ClCCl>[N:11]1([C:15]2[N:23]([C:24]3[CH:25]=[CH:26][CH:27]=[CH:28][CH:29]=3)[C:18]3=[N:19][CH:20]=[CH:21][CH:22]=[C:17]3[C:16]=2[CH:30]=[O:31])[CH2:12][CH2:13][CH2:14][NH:8][CH2:9][CH2:10]1A solution of 4-(3-formyl-1-phenyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-[1,4]diazepane-1-carboxylic acid tert-butyl ester (330 mg, 0.786 mmol) in dichloromethane (20 mL) is treated with trifluoroacetic acid (0.60 mL, 6.04 mmol). The resulting solution is allowed to stir at room temperature for 22 hours before treating the reaction with a further aliquot of trifluoroacetic acid (0.60 mL, 6.04 mmol). After stirring for a further 18 hours, the reaction mixture is evaporated to give a gooey red oil. Trituration of the crude product salt with acetonitrile and ether gives 285 mg of 2-[1,4]diazepan-1-yl-1-phenyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde; trifluoro-acetic acid salt as a pink solid (84% yield). LC/MS: retention time 2.25 min, m/e 321 (M+H). 1H NMR (300 MHz, DMSO-d6): 10.15 (1H, s), 8.60 (2H, br.s), 8.36 (1H, dd), 8.08 (1H, dd), 7.63-7.48 (5H, m), 7.22 (1H, dd), 3.63-3.48 (4H, m), 3.11-2.95 (4H, m), 1.81 (2H, m).
読み込み中…
